中国临床药理学杂志Issue(10)：949-951,3.DOI:10.13699/j.cnki.1001-6821.2014.10.024
多西他赛对比吉西他滨联合顺铂方案治疗非小细胞肺癌临床疗效
Preoperative adjuvant GP chemotherapy regimen vs DP chemotherapy regimen in the treatment of non -small cell lung cancer
潘锋君 1田伟强 1吴小芬 1喻光懋 2方伟钧1
作者信息
- 1. 浙江省丽水市中心医院，药学部 323000
- 2. 绍兴市人民医院，浙江大学绍兴医院，胸心外科 312000
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of DP vs GP regimen with preoperative adjuvant chemotherapy on central stage Ⅲ a non -small cell lung cancer (NSCLC).Methods Fifty -eight cases of central stage Ⅲ a NSCLC patients were recruited in this prospective study.All the cases were randomly divided into DP group (n =27) and GP group (n =31).Patients in DP group were treated with 75 mg・ m-2 of docetaxel and cisplatin on the first day , 21 days as a cycle.And cases in the GP group received 1000 mg・ m 2 of gemcitabine on the first and eighth day as well as 70 mg・ m-2 of cisplatin by intravenous infusion on day one, 28 days as a cycle.Patients in both groups received 2 -3 cy-cles adjuvant chemotherapy.Results The objective response rate and operative rate in DP and GP were 44.4% (12 /27)vs 38.7%(12 /31) and 66.7%(18 /27)vs 54.8%(17 /31)respectively, which demonstrated no statistical difference between the two groups were observed .The Ⅲ/Ⅳ hematologic toxicity were 11.1%(3 /27) and 29.0%(9 /31) in DP and GP regimen respectively, which showed it was much higher in GP regimen ( P <0.05) .Conclusion There was no significant clinical efficacy in the DP and GP chemotherapy regimens for the treatment of central stage Ⅲa NSCLC, but there is a lower risk of developing Ⅲ/Ⅳhematologic toxicity in DP regimen.关键词
术前辅助化疗/GP 方案/非小细胞肺癌Key words
preoperative adjuvant chemotherapy/GP chemotherapy regiment/non -small cell lung carcinoma分类
医药卫生引用本文复制引用
潘锋君,田伟强,吴小芬,喻光懋,方伟钧..多西他赛对比吉西他滨联合顺铂方案治疗非小细胞肺癌临床疗效[J].中国临床药理学杂志,2014,(10):949-951,3.
